JNJ

Johnson & Johnson's stock has increased approximately 43% over the past year. The FDA approved Icotyde for plaque psoriasis, and the European Commission approved AKEEGA for prostate cancer. The Ottava surgical robot met safety and performance endpoints in a gastric bypass study. Management is considering selling its DePuy Synthes orthopedics unit. CVS recently dropped Stelara from its main formulary. The stock price as of May 5, 2026, was $225.55 per share, an increase of 46.02% from $154.47 per share on May 6, 2025. J&J shares decreased to $223.74 USD, the lowest since January 2026, as of May 4, 2026.